Kyntra Bio (KYNB) Return on Sales (2014 - 2026)

Kyntra Bio (KYNB) posted Return on Sales of 0.0% for Q1 2026, down 105.78% sequentially from 0.0% in Q4 2025, and down 8.0% YoY from 0.0% in Q1 2025.

Kyntra Bio (KYNB) Return on Sales (2014 - 2026) Analysis & Trends

Kyntra Bio has reported Return on Sales for 13 years, with the latest figure at 0.0% in Q1 2026.

Quarterly Return on Sales fell 8.0% year-over-year to 0.0% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 0.3% (up 12.0% YoY) and the FY2025 annual result came in at 0.38%, up 34.0% from the prior year.
Return on Sales eased to 0.0% in Q1 2026 per KYNB's latest filing, from 0.0% in the prior quarter.
Over five years, Return on Sales peaked at 2.54% in Q3 2024 and troughed at 0.46% in Q1 2023.
A 5-year average of 0.29% and a median of 0.0% in 2025 frame the typical range for Return on Sales.
The sharpest annual moves came in 2024 and 2025: Return on Sales surged 255 bps in 2024, then tumbled 74 bps in 2025.
Over 5 years, Return on Sales stood at 0.08% in 2022, then surged by 116 bps to 0.01% in 2023, then soared by 575 bps to 0.08% in 2024, then slumped by 96 bps to 0.0% in 2025, then tumbled by 106 bps to 0.0% in 2026.
According to Business Quant data, Return on Sales over the past three periods registered 0.0%, 0.0%, and 1.99% for Q1 2026, Q4 2025, and Q3 2025 respectively.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROS (Qtr)
1	Vertex Pharmaceuticals	137.11 Bn	129.26 Bn	2.84 Bn	0.00%
2	Regeneron Pharmaceuticals	84.98 Bn	76.99 Bn	3.93 Bn	0.00%
3	Argenx Se	64.52 Bn	59.33 Bn	1.37 Bn	0.00%
4	Moderna	53.23 Bn	48.09 Bn	52.00 Mn	-0.05%
5	BeOne Medicines	41.23 Bn	36.14 Bn	1.53 Bn	0.00%
6	Alnylam Pharmaceuticals	30.65 Bn	27.34 Bn	992.69 Mn	0.00%
7	Insmed	27.15 Bn	25.99 Bn	358.27 Mn	0.00%
8	Royalty Pharma	26.98 Bn	26.14 Bn	-	0.00%
9	BioNTech SE	26.78 Bn	8.39 Bn	668.28 Mn	0.00%
10	Kyntra Bio	29.83 Mn	29.83 Mn	1.47 Mn	0.08%

Download Data